NASDAQ:IMNP Immune Pharmaceuticals (IMNP) Stock Price, News & Analysis → Are you prepared for a financial lockdown? (From Weiss Ratings) (Ad) Free IMNP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume12.29 million shsMarket Capitalization$8.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immune Pharmaceuticals alerts: Email Address Ad Weiss RatingsRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and radically change life in America as we know it today. And a Draconian set of technologies that could impose a new kind of financial surveillance in America. Click here to learn more. About Immune Pharmaceuticals Stock (NASDAQ:IMNP)Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.Read More Ad Weiss RatingsRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and radically change life in America as we know it today. And a Draconian set of technologies that could impose a new kind of financial surveillance in America. Click here to learn more. IMNP Stock News HeadlinesMay 22, 2024 | msn.comDrug Helps Reprogram Macrophage Immune Cells, Suppress Prostate and Bladder Tumor GrowthMay 13, 2024 | bloomberg.comAC Immune and Takeda Sign $2.2 Billion Alzheimer’s Drug DealApril 23, 2024 | msn.comIncyte to acquire immune-focused drug developer EscientApril 11, 2024 | msn.comVertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says.April 11, 2024 | msn.comThese Stocks Are Moving the Most Today: Alpine Immune, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 11, 2024 | msn.comThese Stocks Are Moving the Most Today: Alpine Immune, Vertex, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 2, 2024 | markets.businessinsider.comOSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of ImmunologyDecember 15, 2023 | tmcnet.comAC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b TrialDecember 15, 2023 | markets.businessinsider.comAC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b TrialSeptember 14, 2023 | benzinga.comImmune Health Supplements Market US$ 63,457.4 Million Valuation in 2033, Experiencing an Impressive CAGR of 10.4% | Future Market Insights Inc.June 8, 2023 | es-us.finanzas.yahoo.comOrgan Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market ResearchJune 6, 2023 | finanznachrichten.deTheralase Technologies Inc.: Theralase Announces Appointment of New Independent DirectorJune 6, 2023 | finance.yahoo.comTheralase(R) Announces Appointment of New Independent DirectorJune 5, 2023 | msn.comSeveral Down syndrome features may be linked to a hyperactive antiviral immune response – new researchJune 2, 2023 | finanznachrichten.deKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public OfferingJune 2, 2023 | finance.yahoo.comKiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public OfferingJune 1, 2023 | finanznachrichten.deMedexus Pharmaceuticals Inc.: Medexus to Participate in the LD Micro Invitational XIIIJune 1, 2023 | finance.yahoo.comBristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?June 1, 2023 | markets.businessinsider.comHookipa Pharma (HOOK) Gets a Buy from JMP SecuritiesMay 30, 2023 | markets.businessinsider.comPhanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, as Chief Medical OfficerMay 29, 2023 | markets.businessinsider.comX4 Pharmaceuticals (XFOR) Gets a Buy from Stifel NicolausMay 27, 2023 | nasdaq.comHC Wainwright & Co. Reiterates Eledon Pharmaceuticals (ELDN) Buy RecommendationMay 23, 2023 | finance.yahoo.comCalciMedica Expands Executive Team with New AppointmentsMay 17, 2023 | technews.tmcnet.comBiotech Entrepreneur and Venture Capitalist Dinesh Patel Discusses Therapeutics and Medical Devices with CancerVAX CEO Ryan DaviesMay 17, 2023 | marketwatch.comMyocardial Infarction Drugs Market Size and Projection from 2023 to 2030See More Headlines Receive IMNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2018Today6/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:IMNP Previous SymbolOTCMKTS:EPCT CUSIPN/A CIK1208261 Webwww.immunepharmaceuticals.com Phone201-464-2677FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares49,313,000Free FloatN/AMarket Cap$8.14 million OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Elliot M. Maza CPA (Age 62)J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director Dr. Anthony S. Fiorino (Age 51)COO & Chief Medical Officer Mr. Christine J. PetragliaDirector of Investor RelationsMs. Anna Baran-Djokovic J.D.Director of Corp. AffairsDr. Miri Ben-AmiPres of Immune Oncology Pharmaceuticals IncKey CompetitorsProMIS NeurosciencesNASDAQ:PMNLisata TherapeuticsNASDAQ:LSTABioVieNASDAQ:BIVIAcasti PharmaNASDAQ:ACSTEnlivex TherapeuticsNASDAQ:ENLVView All Competitors IMNP Stock Analysis - Frequently Asked Questions How were Immune Pharmaceuticals' earnings last quarter? Immune Pharmaceuticals Inc (NASDAQ:IMNP) released its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05. What other stocks do shareholders of Immune Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Pharmaceuticals investors own include Neovasc (NVCN), LadRx (CYTR), Biopharmx (BPMX), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Pernix Therapeutics (PTX), Sorrento Therapeutics (SRNE), Novavax (NVAX), DryShips (DRYS) and Heat Biologics (HTBX). This page (NASDAQ:IMNP) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immune Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.